Patents by Inventor Samuel E. Perkins

Samuel E. Perkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7855272
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: December 21, 2010
    Assignees: Bioresearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7834151
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: November 16, 2010
    Assignee: The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7816494
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: October 19, 2010
    Assignee: The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Publication number: 20100113349
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 6, 2010
    Inventors: Joseph M. PATTI, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Publication number: 20100081616
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: April 1, 2010
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Publication number: 20100008943
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: January 14, 2010
    Inventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7381793
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: June 3, 2008
    Assignees: Inhibitex, Inc., BioResearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Publication number: 20040254354
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: December 24, 2003
    Publication date: December 16, 2004
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Patent number: 6680195
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: January 20, 2004
    Assignees: Inhibitex, Inc., Bioresearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins